

116TH CONGRESS
1ST SESSION

H. R. 4667

To amend the 21st Century Cures Act to reauthorize funding for NIH innovation projects, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

OCTOBER 11, 2019

Ms. SHERRILL (for herself, Mr. LEVIN of California, and Ms. SPANBERGER) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To amend the 21st Century Cures Act to reauthorize funding for NIH innovation projects, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Biomedical Innovation
5 Expansion Act of 2019”.

6 **SEC. 2. REAUTHORIZATION OF NIH INNOVATION PROJ-**
7 **ECTS.**

8 (a) TRANSFERS.—Section 1001(b)(2)(A) of the 21st
9 Century Cures Act (Public Law 114–255) is amended by

1 striking clauses (v) through (x) and inserting the fol-
2 lowing:

3 “(v) For fiscal year 2021,
4 \$854,000,000.

5 “(vi) For fiscal year 2022,
6 \$1,051,000,000.

7 “(vii) For fiscal year 2023,
8 \$1,345,000,000.

9 “(viii) For fiscal year 2024,
10 \$1,271,000,000.

11 “(ix) For fiscal year 2025,
12 \$1,301,000,000.

13 “(x) For fiscal year 2026,
14 \$1,306,000,000.

15 “(xi) For fiscal year 2027,
16 \$1,336,000,000.

17 “(xii) For fiscal year 2028,
18 \$1,376,000,000.

19 “(xiii) For fiscal year 2029,
20 \$1,436,000,000.

21 “(xiv) For fiscal year 2030,
22 \$1,469,000,000.”.

23 (b) AUTHORIZATION OF APPROPRIATIONS.—Section
24 1001(b)(3)(A) of the 21st Century Cures Act (Public Law

1 114–255) is amended by striking “2026” and inserting
 2 “2030”.

3 (c) OFFSETTING FUTURE APPROPRIATIONS.—Sec-
 4 tion 1001(b)(3)(B) of the 21st Century Cures Act (Public
 5 Law 114–255) is amended by striking “2026” and insert-
 6 ing “2030”.

7 (d) NIH INNOVATION PROJECTS.—Section
 8 1001(b)(4) of the 21st Century Cures Act (Public Law
 9 114–255) is amended—

10 (1) in the matter preceding subparagraph (A),
 11 by striking “2026” and inserting “2030”;

12 (2) in subparagraph (A)—

13 (A) in the matter preceding clause (i), by
 14 striking “\$1,455,000,000” and inserting
 15 “\$4,413,000,000”; and

16 (B) by striking clauses (v) through (x) and
 17 inserting the following:

18 “(v) For fiscal year 2021,
 19 \$209,000,000.

20 “(vi) For fiscal year 2022,
 21 \$300,000,000.

22 “(vii) For fiscal year 2023,
 23 \$419,000,000.

24 “(viii) For each fiscal years 2024
 25 through 2030, \$430,000,000.”;

1 (3) in subparagraph (B)—

2 (A) in the matter preceding clause (i), by
3 striking “\$1,511,000,000” and inserting
4 “\$4,428,000,000”; and

5 (B) by striking clauses (v) through (x) and
6 inserting the following:

7 “(v) For fiscal year 2021,
8 \$250,000,000.

9 “(vi) For fiscal year 2022,
10 \$302,000,000.

11 “(vii) For fiscal year 2023,
12 \$450,000,000.

13 “(viii) For each of fiscal years 2024,
14 2025, and 2026, \$400,000,000.

15 “(ix) For fiscal year 2027,
16 \$425,000,000.

17 “(x) For fiscal years 2028,
18 \$450,000,000.

19 “(xi) For each of fiscal years 2029
20 and 2030, \$500,000,000.”;

21 (4) in subparagraph (C)—

22 (A) in the matter preceding clause (i), by
23 striking “\$1,800,000,000” and inserting
24 “\$3,312,000,000”; and

1 (B) by amending clause (vii) to read as fol-
2 lows:

3 “(vii) For each of fiscal years 2023
4 through 2030, \$216,000,000.”;

5 (5) in subparagraph (D)—

6 (A) in the matter preceding clause (i), by
7 striking “\$30,000,000” and inserting
8 “\$250,000,000”; and

9 (B) by striking clause (iv) and inserting
10 the following:

11 “(iv) For each of fiscal years 2021,
12 2022, and 2023, \$50,000,000.

13 “(v) For each of fiscal years 2024
14 through 2030, \$10,000,000.”; and

15 (6) by adding at the end the following:

16 “(E) To support research related to com-
17 bating antimicrobial resistance and antibiotic
18 resistant bacteria, not to exceed a total of
19 \$1,635,000,000, as follows:

20 “(i) For fiscal year 2021,
21 \$100,000,000.

22 “(ii) For each of fiscal years 2022
23 through 2024, \$150,000,000.

24 “(iii) For each of fiscal years 2025
25 through 2027, \$175,000,000.

1 “(iv) For each of fiscal years 2028
2 and 2029, \$180,000,000.

3 “(v) For fiscal year 2030,
4 \$200,000,000.

5 “(F) To support research and research ac-
6 tivities related to rare diseases or conditions,
7 not to exceed a total of \$758,000,000, as fol-
8 lows:

9 “(i) For fiscal year 2021,
10 \$50,000,000.

11 “(ii) For fiscal year 2022,
12 \$55,000,000.

13 “(iii) For fiscal year 2023,
14 \$60,000,000.

15 “(iv) For fiscal year 2024,
16 \$65,000,000.

17 “(v) For fiscal year 2025,
18 \$70,000,000.

19 “(vi) For fiscal year 2026,
20 \$75,000,000.

21 “(vii) For fiscal year 2027,
22 \$80,000,000.

23 “(viii) For fiscal year 2028,
24 \$90,000,000.

1 “(ix) For fiscal year 2029,
2 \$100,000,000.

3 “(x) For fiscal year 2030,
4 \$113,000,000.”.

5 (e) WORKPLAN.—Section 1001(c)(1)(A) of the 21st
6 Century Cures Act (Public Law 114–255) is amended by
7 striking “2026” and inserting “2030”.

8 (f) RECOMMENDATIONS.—Section 1001(c)(1)(C)(i)
9 of the 21st Century Cures Act (Public Law 114–255) is
10 amended by striking “2026” and inserting “2030”.

11 (g) ANNUAL REPORTS.—Section 1001(c)(2)(A) of
12 the 21st Century Cures Act (Public Law 114–255) is
13 amended by striking “2027” and inserting “2030”.

14 (h) SUNSET.—Section 1001(e) of the 21st Century
15 Cures Act (Public Law 114–255) is amended by striking
16 “September 30, 2026” and inserting “September 30,
17 2030”.

○